These preliminary results suggest that ERK5i switches the protumoral phenotype of TRAIL to an antitumoral (apoptotic) phenotype in NSCLC harboring activating KRAS mutations. This evidence concerns the gene TNFSF10 and non-small cell lung carcinoma.